| Literature DB >> 19997602 |
Alejandro J Moyano1, Andrea M Smania.
Abstract
In Pseudomonas aeruginosa, conversion to the mucoid phenotype marks the onset of an irreversible state of the infection in Cystic Fibrosis (CF) patients. The main pathway for mucoid conversion is mutagenesis of the mucA gene, frequently due to -1 bp deletions in a simple sequence repeat (SSR) of 5 Gs (G(5)-SSR(426)). We have recently observed that this mucA mutation is particularly accentuated in Mismatch Repair System (MRS)-deficient cells grown in vitro. Interestingly, previous reports have shown a high prevalence of hypermutable MRS-deficient strains occurring naturally in CF chronic lung infections. Here, we used mucA as a forward mutation model to systematically evaluate the role of G(5)-SSR(426) in conversion to mucoidy in a MRS-deficient background, with this being the first analysis combining SSR-dependent localized hypermutability and the acquisition of a particular virulence/persistence trait in P. aeruginosa. In this study, mucA alleles were engineered with different contents of G:C SSRs, and tested for their effect on the mucoid conversion frequency and mucA mutational spectra in a mutS-deficient strain of P. aeruginosa. Importantly, deletion of G(5)-SSR(426) severely reduced the emergence frequency of mucoid variants, with no preferential site of mutagenesis within mucA. Moreover, although mutagenesis in mucA was not totally removed, this was no longer the main pathway for mucoid conversion, suggesting that G(5)-SSR(426) biased mutations towards mucA. Mutagenesis in mucA was restored by the addition of a new SSR (C(6)-SSR(431)), and even synergistically increased when G(5)-SSR(426) and C(6)-SSR(431) were present simultaneously, with the mucA mutations being restricted to -1 bp deletions within any of both G:C SSRs. These results confirm a critical role for G(5)-SSR(426) enhancing the mutagenic process of mucA in MRS-deficient cells, and shed light on another mechanism, the SSR- localized hypermutability, contributing to mucoid conversion in P. aeruginosa.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19997602 PMCID: PMC2781719 DOI: 10.1371/journal.pone.0008203
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Site directed mutagenesis on the mucA gene.
A fragment of the P. aeruginosa mucA gene where the site directed mutagenesis was performed is shown. Base changes (bold face) were designed in order to maintain the amino acidic sequence unaltered (shown below), and codons were chosen that are commonly used by P. aeruginosa. The premature stop codon generated by a hypothetical −1 bp deletion between positions 426 and 436 of mucA is underlined. Wild type mucA allele from MPA strain with G5SSR426 is highlighted in yellow. The mucAT1 allele from strain MPA-T1 was generated by replacing G-to-A at 426 and G-to-T at 429, thus eliminating G5SSR426. The mucAT2 allele from strain MPA-T2 was generated by replacing G-to-A at 426 and G-to-T at 429 (eliminating G5SSR426), and G-to-C at 432 and 435 to generate C6SSR431 (highlighted in blue). The mucAT3 allele from strain MPA-T3 was generated by replacing G-to-C at 432 and 435 to generate C6SSR431 (highlighted in blue), and maintaining G5SSR426 (highlighted in yellow) unaltered.
Figure 2Role of SSRs in P. aeruginosa mucoid conversion.
(A) Mucoid variants, visualized as mucous droplet-like colonies emerging from MPA, MPA-T1, MPA-T2 and MPA-T3 strains plated onto MMA plates. (B) Relative emergence of mucoid variants obtained from MPA-T1, MPA-T2 and MPA-T3 strains. The values were compared to those obtained for the MPA strain. *Values for MPA-T1 and MPA-T3 were significantly different (p<0.05, as determined by the t-test) from that of MPA. (C) Spectrum of mucA mutations observed in mucoid variants obtained from MPA, MPA-T1, MPA-T2 and MPA-T3 strains. Bars indicate the observed percentage for each kind of mutation of the total number of mucoid clones analyzed in each strain (total clones analyzed: MPA, 11; MPA-T1, 13; MPA-T2, 13; and MPA-T3, 15). Bars in yellow indicate those mucoid variants that occurred in the absence of mucA alterations. The observed mutations included base substitutions (gray) and −1 bp deletions in mononucleotide G:C SSRs (blue).
Mutations in the mucA gene of mucoid isolates from strains MPA, MPA-T1, MPA-T2 and MPA-T3.
| Strain and | Stop | Number of isolates |
|
| ||
| ΔG at 426 | TGA at 440 | 6 |
| C→T at 424 | TAG at 424 | 1 |
| C→T at 436 | TAG at 436 | 1 |
| None | none | 3 |
|
| ||
| ΔC at 362 | TGA at 385 | 1 |
| G→A at 249 | TGA at 247 | 1 |
| C→T at 367 | TAG at 367 | 1 |
| C→T at 424 | TAG at 424 | 1 |
| C→T at 505 | TAG at 505 | 1 |
| none | none | 9 |
|
| ||
| ΔC at 431 | TGA at 440 | 12 |
| none | none | 1 |
|
| ||
| ΔG at 426 | TGA at 440 | 5 |
| ΔC at 431 | TGA at 440 | 10 |
ΔG at 426 corresponds to a −1 bp deletion within G5SSR426; ΔC at 362 corresponds to a −1 bp deletion within a mononucleotide SSR of four Cs from 362 to 365 (C4SSR362); ΔC at 431 corresponds to a −1 bp deletion within C6SSR431. “None” refers to conversion to mucoidy occurring in the absence of mucA mutations. The nature of these non-mucA alterations leading to a mucoid phenotype was not investigated in this work.
Stop codon produced at the site of the mutation by substitutions or placed in frame by frameshift mutations.
Classification of mucA mutations reported in different studies for P. aeruginosa CF isolates.
| Location | Analyzed isolates | Kinds of mutations in | −1 bp in G5SSR430/Total −1 bp deletions (%) | Reference | |||
| Transi-tions | Transver-sions | −1 bp deletions | Other indels | ||||
| USA | 41 | 34 | 9 | 32 | 25 | 67 |
|
| Australia | 22 | 50 | 0 | 29 | 21 | 57 |
|
| Germany | 14 | 41 | 0 | 53 | 6 | 88 |
|
| Scandinavia | 148 | 46 | 1 | 33 | 20 | 80 |
|
| Argentina | 24 | 29 | 8 | 63 | 0 | 67 | Unpublished |
For each study, only the isolates for which the mucA mutations were reported were considered in the analysis.
Insertion or deletion mutations different from −1 bp deletions.
Bacterial strains, plasmids and oligonucleotides used in this study.
| Strains, vectors and primers | Description | Source or Reference |
|
| ||
|
| ||
| MPA |
|
|
| MPA-T1 | TcR, MPA carrying a | This study |
| MPA-T2 | TcR, MPA carrying a | This study |
| MPA-T3 | TcR, MPA carrying a | This study |
|
| ||
| XL1-Blue | host strain for DNA manipulation |
|
| SY327 λ | RfR; recipient to propagate pKNG-101 derivatives |
|
| SM10 λ | Recipient for conjugal transfer of pKNG-101 derivatives |
|
|
| ||
| pGEM-T Easy | ApR; PCR product cloning vector | Promega |
| pGEM- | ApR; | This study |
| pGEM- | ApR; | This study |
| pGEM- | ApR; | This study |
| pKNG101 | SmR, suicide delivery plasmid containing |
|
| pKNG- | SmR, SucS, pKNG101 carrying | This study |
| pKNG- | SmR, SucS, pKNG101 carrying | This study |
| pKNG- | SmR, SucS, pKNG101 carrying | This study |
|
| ||
| MucPA-F |
|
|
| MucPA-R |
|
|
| MucBamHI-F |
| This study |
| MucXbaI-R |
| This study |
| MucT1-F |
| This study |
| MucT1-R |
| This study |
| MucT2-F |
| This study |
| MucT2-R |
| This study |
| MucT3-F |
| This study |
| MucT3-R |
| This study |
Resistance markers: Tc, tetracycline; Rf, rifampin; Sm, streptomycin; Ap, ampicillin; Suc, sucrose.